Stifel, the American investment bank, has initiated coverage of hVIVO PLC, the contract research organisation (CRO) specialising in human challenge clinical trials (HCTs), with a target share price of 27p.
This represents a 42% premium over the firm's current share price of 19p. The bullish stance from Stifel comes as hVIVO continues to demonstrate robust financial performance and strategic value in the pharmaceutical and biotechnology sectors.
88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) told investors it has been busy across its Alaskan North Slope portfolio, albeit the explorer’s focus is “firmly” on the upcoming well test at the Hickory-1 site.
The Hickory-1 well will be flow tested in the first quarter of 2024, the company highlighted in Thursday’s projects update.